Crizotinib in ROS1 and MET Deregulated NSCLC--Letter,Clinical Cancer Research

当前位置： X-MOL 学术 › Clin. Cancer Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Crizotinib in ROS1 and MET Deregulated NSCLC--Letter
Clinical Cancer Research ( IF 10.0 ) Pub Date : 2020-04-01 , DOI: 10.1158/1078-0432.ccr-19-3740
Marcel Wiesweg _{1,

2} , Martin Schuler _{1,

2,

3} , Hans-Ulrich Schildhaus ₄

Affiliation

In the METROS trial, Landi and colleagues evaluated the efficacy of crizotinib in advanced non–small cell lung cancer (NSCLC) harboring ROS1 rearrangements or MET dysregulation ([1][1]). A total of 505 patients were screened and 10 patients entered the trial with cancers harboring MET exon 14

中文翻译：